Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and …

L Peyrin-Biroulet, S Danese, M Argollo… - Clinical …, 2019 - Elsevier
Background & Aims Vedolizumab is effective and safe for the treatment of Crohn's disease
(CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response …

Macrophage-based nanotherapeutic strategies in ulcerative colitis

J Zhang, Y Zhao, T Hou, H Zeng, D Kalambhe… - Journal of Controlled …, 2020 - Elsevier
Macrophages, an important component of the innate immune response, are a key regulator
of intestinal microenvironment homeostasis. These cells essentially contribute to chronic …

Next generation of small molecules in inflammatory bowel disease

P Olivera, S Danese, L Peyrin-Biroulet - Gut, 2017 - gut.bmj.com
Inflammatory bowel disease (IBD) encompasses two major entities: ulcerative colitis (UC)
and Crohn's disease (CD). 1 Both are chronic, progressive, disabling conditions that require …

Novel therapeutic targets for inflammatory bowel disease

M Argollo, G Fiorino, P Hindryckx, L Peyrin-Biroulet… - Journal of …, 2017 - Elsevier
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis
(UC), are immune mediated conditions associated with progressive damage of the inflamed …

[HTML][HTML] The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for Inflammatory Bowel Diseases

M Body-Malapel, M Djouina, C Waxin, A Langlois… - Mucosal …, 2019 - Elsevier
Abstract Inflammatory Bowel Diseases (IBD) are chronic inflammatory conditions of the
intestinal tract. IBD are believed to result from an inappropriate immune response against …

Prediction of response to biological treatment with monoclonal antibodies in severe asthma

JA Kroes, SW Zielhuis, EN Van Roon… - Biochemical …, 2020 - Elsevier
In recent years, major developments have occurred in severe asthma management.
Different asthma phenotypes and subgroups have been identified and new treatment …

Extracellular vesicles in inflammatory bowel disease: small particles, big players

M Valter, S Verstockt, JA Finalet Ferreiro… - Journal of Crohn's …, 2021 - academic.oup.com
Extracellular vesicles are nanovesicles released by many cell types into the extracellular
space. They are important mediators of intercellular communication, enabling the functional …

[HTML][HTML] Proteomics and lipidomics in inflammatory bowel disease research: from mechanistic insights to biomarker identification

B Titz, RM Gadaleta, G Lo Sasso, A Elamin… - International Journal of …, 2018 - mdpi.com
Inflammatory bowel disease (IBD) represents a group of progressive disorders characterized
by recurrent chronic inflammation of the gut. Ulcerative colitis and Crohn′ s disease are the …

[HTML][HTML] Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: a practical overview

P Hindryckx, G Novak, N Vande Casteele, R Khanna… - Drugs, 2017 - Springer
The introduction of biologic therapy has revolutionized the treatment of inflammatory bowel
disease (IBD). However, like all therapeutic proteins, monoclonal antibodies have …

Clinical pharmacology of janus kinase inhibitors in inflammatory bowel disease

PLC Lefevre, N Vande Casteele - Journal of Crohn's and Colitis, 2020 - academic.oup.com
Inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are chronic
inflammatory disorders of the gastrointestinal tract which are characterised, in part, by an …